Cocrystal Pharma, Inc. (COCP)
1.16
+0.01
(+0.87%)
USD |
NASDAQ |
Sep 25, 16:00
1.16
0.00 (0.00%)
After-Hours: 17:53
Cocrystal Pharma Research and Development Expense (Annual) : 5.055M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 5.055M |
| December 31, 2024 | 12.54M |
| December 31, 2023 | 15.17M |
| December 31, 2022 | 12.39M |
| December 31, 2021 | 8.412M |
| December 31, 2020 | 5.971M |
| December 31, 2019 | 3.75M |
| December 31, 2018 | 4.617M |
| Date | Value |
|---|---|
| December 31, 2017 | 5.721M |
| December 31, 2016 | 101.48M |
| December 31, 2015 | 47.26M |
| December 31, 2014 | 4.071M |
| December 31, 2013 | 0.0175M |
| December 31, 2012 | 0.7431M |
| December 31, 2011 | 0.3996M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| CNBX Pharmaceuticals, Inc. | 0.00 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 282.90M |
| Fulcrum Therapeutics, Inc. | 54.71M |
| Definium Therapeutics, Inc. | 117.66M |